Albert B. Sabin Vaccine Institute, Inc. (the)
Albert B. Sabin Vaccine Institute, Inc. (the) received $266.2M in federal prime contract obligations in the 12 months ending Oct 5, 2026, up 278.2% from $70.4M the year before, and $497.0M since FY2022. Its largest customer is the Department of Health and Human Services.
See 1 contracts ending in the next 18 months ↓Contractor details
- Unique Entity ID (UEI)
- H5E8NU6N2HZ5
- CAGE code
- 5MPW2
- Doing business as
- Sabin Vaccine Insitute
- Headquarters
- Washington, DC
- Business size
- Other Than Small Business
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Markets where it ranks top 10
Agency and NAICS markets where this UEI is one of the ten largest primes in the latest 12 months.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Health and Human Services | $266.2M | $497.0M |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
| NAICS | Industry | Latest 12 mo | Since FY2022 |
|---|---|---|---|
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | $266.2M | $497.0M |
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| 6505 | Drugs and Biologicals | $263.6M |
| AN42 | Health R&D services; Health Care - other; Applied Research | $163.1M |
| AN73 | R&D- medical: Specialized Medical Services (Advanced Development) | $70.3M |
Contracts ending in the next 18 months
This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.
| Award | Agency | Obligated | Current end |
|---|---|---|---|
| 75A50119C00055 | Department of Health and Human Services THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $70.3M | Sep 30, 2027 |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 75A50126C00001 | Department of Health and Human Services STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP) | $223.8M | May 5, 2026 |
| 75A50123C00010 | Department of Health and Human Services THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE… | $35.0M | Dec 29, 2022 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.